Search Results

Y-90 Radioembolization Compared With Chemoembolization for Hepatocellular Carcinoma

August 31, 2016—Online ahead of print in Gastroenterology, Riad Salem, MD, et al published findings from a randomized, phase 2 study comparing the effects of treating patients with hepatocellular carcinoma (HCC) with conventional transarterial chemoembolization (cTACE) versus a minimally invasive radioembolization procedure using implanted radioactive micron-sized particles loaded with yttrium-90 (Y-90) inside the blood vessels that supply a tumor.

Northwestern 15-Year Experience Informs Institutional Decision to Adopt Y-90 TARE as Primary Treatment for HCC

December 26, 2017— Findings from a study of yttrium-90 (Y-90) transarterial radioembolization (TARE) were published by Riad Salem, MD, et al online ahead of print in Hepatology.

Y-90 Radioembolization Studied for Locally Advanced HCC With Portal Vein Thrombosis

December 21, 2017—Online in Journal of Nuclear Medicine, Nadine Abouchaleh et al reported survival outcomes for advanced stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with yttrium-90 (Y-90) radioembolization.

Radiation Segmentectomy Studied to Treat Liver Cancer

April 27, 2018—The Radiological Society of North America (RSNA) announced that findings from a study of radiation segmentectomy (RS) as a curative treatment option for patients with early stage hepatocellular carcinoma (HCC) were published online by Robert J. Lewandowski, MD, et al in RSNA's Radiology. The study's Senior Investigator is Riad Salem, MD, who is Chief of Vascular Interventional Radiology in the Department of Radiology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Boston Scientific’s TheraSphere Y-90 Glass Microspheres Evaluated in Phase 3 EPOCH Trial to Treat Metastatic Colorectal Cancer

September 20, 2021—Boston Scientific Corporation announced that the EPOCH clinical trial of the company’s TheraSphere yttrium-90 (Y-90) glass microspheres met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) of patients with metastatic colorectal cancer (mCRC) of the liver.

Boston Scientific's Direxion Torqueable Microcatheter Receives FDA Clearance and CE Mark Approval

November 19, 2013—Boston Scientific Corporation (Natick, MA) announced that it has received US Food and Drug Administration clearance and European CE Mark approval for its Direxion torqueable microcatheter, part of its portfolio of peripheral embolization technologies used primarily by interventional radiologists to treat liver cancer, uterine fibroids, and other challenging conditions.  According to Boston Scientific, the Direxion device is designed to facilitate selective access and delivery of diagnostic, embolic, and therapeutic materials into the peripheral vasculature.

FDA Approves Boston Scientific’s TheraSphere Y-90 Glass Microsphere to Treat HCC

March 18, 2021—Boston Scientific Corporation announced it has received FDA approval of the TheraSphere Y-90 glass microspheres for the treatment of patients with hepatocellular carcinoma (HCC).